<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619341</url>
  </required_header>
  <id_info>
    <org_study_id>FMHS 17-0622</org_study_id>
    <nct_id>NCT05619341</nct_id>
  </id_info>
  <brief_title>Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON)</brief_title>
  <acronym>EON</acronym>
  <official_title>Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether slowing the rate of delivery of inulin with either psyllium or divided dosing&#xD;
      of inulin, will reduce colonic gas production as compared to inulin combined with placebo.&#xD;
&#xD;
      To obtain pilot data on link between habitual diet and fermentation of inulin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our challenge is to understand how fibre interacts with whole-gut function to alter colonic&#xD;
      fermentation of fermentable oligo-di-mono-saccharides and polyhydric alcohols (FODMAPs). We&#xD;
      have previously performed the study entitled the Effect of modified Cellulose On COlonic&#xD;
      fermentAtion of inulin (COCOA) in which a modified methylcellulose (food grade product&#xD;
      -modified celluloses- which can form gels at body temperature ) was used and showed some&#xD;
      reduction, but this was not statistically significant, and much less than with psyllium. We&#xD;
      wish to determine whether slowing delivery of inulin will produce a lowering of breath&#xD;
      hydrogen equivalent to that seen with psyllium. We also found that the breath hydrogen curve&#xD;
      had not shown a consistent fall by 6 hours suggesting that 6 hours was not long enough to&#xD;
      accurately define the area under the curve (AUC). We now plan to use breath sampling bags to&#xD;
      collect breath samples at home to define the breath hydrogen response over whole 24-hour&#xD;
      period post ingestion of test drink. We also hypothesise that the colonic microbiota will&#xD;
      influence the fermentation of inulin and will collect stool samples to allow future work to&#xD;
      correlate microbiota with fermentation rates as part of a separate Medical Research Council&#xD;
      funded study.&#xD;
&#xD;
      Aim Our aim is to test the hypothesis that slowing delivery of inulin will achieve a similar&#xD;
      reduction in breath hydrogen production over the 24 hours following ingestion as seen when&#xD;
      co-administered with psyllium.&#xD;
&#xD;
      Objective The primary objective is to compare the effect of bolus administration of inulin&#xD;
      (co-administrated with psyllium or maltodextrin placebo) with divided dose delivery of inulin&#xD;
      over 6 hours on total gas production over 24 hours.&#xD;
&#xD;
      Secondary Objectives Secondary objectives will be 1) to compare breath hydrogen AUC 0-24h&#xD;
      with values based on AUC 0-6h that was assessed in the previous study (COCOA) to see how much&#xD;
      the shorter period underestimates H2 production; 2) to assess breath methane production AUC&#xD;
      0-24h after consumption of test drinks; and 3) to collect pilot data on habitual dietary&#xD;
      FODMAPs intake to assess whether this alters fermentation of inulin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2022</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3 way cross-over</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>psyllium / maltodextrin added to 500ml water + inulin 20g</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hydrogen production</measure>
    <time_frame>2 days</time_frame>
    <description>AUC 0-24h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Methane production</measure>
    <time_frame>2 days</time_frame>
    <description>AUC 0-24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intake of FOOMDAPS</measure>
    <time_frame>4 days</time_frame>
    <description>24 h food diary X 4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Irritable Bowel</condition>
  <arm_group>
    <arm_group_label>inulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20g inulin in 500ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inulin + psyllium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inulin 20g + 20g psyllium in 500 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inulin divided doses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 g inulin in 62.5ml water given at 45 minute intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>psyllium</intervention_name>
    <description>psyllium 20g</description>
    <arm_group_label>inulin + psyllium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>inulin</intervention_name>
    <description>long chain fructan</description>
    <arm_group_label>inulin</arm_group_label>
    <arm_group_label>inulin + psyllium</arm_group_label>
    <arm_group_label>inulin divided doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 or older.&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
          -  Scoring â‰¤3 (i.e., mild, or less) for symptoms of flatulence, bloating and abdominal&#xD;
             pain in previous 2 weeks using a modified Gastrointestinal Symptom Rating Scale (5).&#xD;
&#xD;
          -  Agrees to consume the meals provided.&#xD;
&#xD;
          -  Agrees to not smoke during the breath hydrogen sampling period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy declared by candidate.&#xD;
&#xD;
          -  History declared by the candidate of pre-existing gastrointestinal disorder that may&#xD;
             affect bowel function.&#xD;
&#xD;
          -  Reported history of previous resection of the oesophagus, stomach, or intestine&#xD;
             (excluding appendix).&#xD;
&#xD;
          -  Intestinal stoma.&#xD;
&#xD;
          -  Any medical condition potentially compromising participation in the study e.g., type 1&#xD;
             diabetes mellitus, respiratory disease limiting ability to use breath hydrogen&#xD;
             analyser, known intolerance to one of the test substances.&#xD;
&#xD;
          -  Will not agree to dietary restrictions required nor consume the standard meals&#xD;
             required during the study day.&#xD;
&#xD;
          -  Unable to stop drugs known to alter GI motility including mebeverine, opiates,&#xD;
             monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel&#xD;
             antagonists for the duration of the study (Selective serotonin reuptake inhibitors,&#xD;
             low dose tricyclic antidepressants, antihistamines, and oral contraceptive pill will&#xD;
             be recorded in the CRF but will not be an exclusion criteria).&#xD;
&#xD;
          -  Participants who are taking antibiotics or probiotics as they might alter gut&#xD;
             microbiota.&#xD;
&#xD;
          -  Poor understanding of English language.&#xD;
&#xD;
          -  Participation in night shift work the week prior to the study day. Night work is&#xD;
             defined as working between midnight and 6.00 AM.&#xD;
&#xD;
          -  Anyone who in the opinion of the investigator is unlikely to be able to comply with&#xD;
             the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance&#xD;
             abuse.&#xD;
&#xD;
          -  Having taken part in a research study in the last 3 months involving invasive&#xD;
             procedures or an inconvenience allowance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alaa Alhasein, BSc</last_name>
    <phone>01159249924</phone>
    <email>ala.alhasein@nottingham.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nottingham Digestive Disease Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaa Alhasani, BSc</last_name>
      <phone>01159429924</phone>
      <email>alyaa11@exmail.nottingham.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Galvin MA, Kiely M, Harrington KE, Robson PJ, Moore R, Flynn A. The North/South Ireland Food Consumption Survey: the dietary fibre intake of Irish adults. Public Health Nutr. 2001 Oct;4(5A):1061-8. doi: 10.1079/phn2001187.</citation>
    <PMID>11820919</PMID>
  </results_reference>
  <results_reference>
    <citation>Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, Quigley EMM, Moayyedi P. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018 Sep;113(9):1290-1300. doi: 10.1038/s41395-018-0195-4. Epub 2018 Jul 26.</citation>
    <PMID>30046155</PMID>
  </results_reference>
  <results_reference>
    <citation>Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P, Marciani L, Gill SK, Warren FJ, Rossi M, Remes-Troche JM, Whelan K, Spiller RC. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut. 2022 May;71(5):919-927. doi: 10.1136/gutjnl-2021-324784. Epub 2021 Aug 5.</citation>
    <PMID>34353864</PMID>
  </results_reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nottingham</investigator_affiliation>
    <investigator_full_name>Robin Spiller</investigator_full_name>
    <investigator_title>Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>fermentation</keyword>
  <keyword>gas</keyword>
  <keyword>colonic</keyword>
  <keyword>inulin</keyword>
  <keyword>psyllium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

